Format

Send to

Choose Destination
Clin Exp Gastroenterol. 2016 Jan 28;9:21-9. doi: 10.2147/CEG.S51902. eCollection 2016.

Fecal calprotectin in inflammatory bowel disease.

Author information

1
Department of Clinical Biochemistry, University Hospital Lewisham, Lewisham, London, UK.
2
Department of Clinical Biochemistry, Viapath at King's College Hospital NHS Foundation Trust, London, UK.

Abstract

Inflammatory bowel disease (IBD) and irritable bowel syndrome share many symptoms. While irritable bowel syndrome is a functional bowel disorder for which no specific treatment is available, the range of effective therapies for IBD is evolving rapidly. Accurate diagnosis of IBD is therefore essential. Clinical assessment, together with various imaging modalities and endoscopy, has been the mainstay of diagnosis for many years. Fecal biomarkers of gastrointestinal inflammation have appeared in the past decade, of which calprotectin, a neutrophil cytosolic protein, has been studied the most. Crohn's disease and ulcerative colitis are chronic remitting and relapsing diseases, and objective assessment of disease activity and response to treatment are important. This review focuses on the use of fecal calprotectin measurements in the diagnosis and monitoring of patients with IBD.

KEYWORDS:

Crohn’s disease; calprotectin; inflammation; inflammatory bowel disease; ulcerative colitis

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center